UBX1967

About Unity Biotechnology

Unity Biotechnology was founded on groundbreaking academic research into cellular senescence as a root cause of age-related diseases. Its mission was to develop selective senolytic medicines, initially focusing on localized delivery for ophthalmologic conditions like diabetic macular edema and neurodegenerative diseases. Despite promising early-stage clinical data and raising significant capital, the company faced clinical setbacks, pivoted its strategy, and ultimately ceased operations in 2024, marking the end of a prominent early player in the longevity therapeutics field.

Therapeutic Areas